Press release content from PR Newswire. The AP news staff was not involved in its creation.
DOORwaY-90 study for SIR-Spheres® therapy as first-line treatment for hepatocellular carcinoma enrolls first patient
May 10, 2021 GMT
Sirtex DOORwaY-90 Study Logo
First prospective multicenter U.S.-based trial for indication expansion of SIR-Spheres® Y-90 resin microspheres taking place in 15 sites across the U.S.
WOBURN, Mass., May 10, 2021 /PRNewswire/ Sirtex Medical (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced that the first patient has been enrolled in DOORwaY-90, a study evaluating the safety and efficacy of selective internal radiation therapy (SIRT) using SIR-Spheres® Y-90 resin microspheres in patients with unresectable hepatocellular carcinoma (HCC).